JPWO2023278520A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023278520A5 JPWO2023278520A5 JP2023580800A JP2023580800A JPWO2023278520A5 JP WO2023278520 A5 JPWO2023278520 A5 JP WO2023278520A5 JP 2023580800 A JP2023580800 A JP 2023580800A JP 2023580800 A JP2023580800 A JP 2023580800A JP WO2023278520 A5 JPWO2023278520 A5 JP WO2023278520A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- amino acid
- acid sequence
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163216753P | 2021-06-30 | 2021-06-30 | |
| US63/216,753 | 2021-06-30 | ||
| PCT/US2022/035441 WO2023278520A1 (en) | 2021-06-30 | 2022-06-29 | Polypeptides targeting cd70-positive cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525492A JP2024525492A (ja) | 2024-07-12 |
| JPWO2023278520A5 true JPWO2023278520A5 (enrdf_load_stackoverflow) | 2025-07-07 |
Family
ID=84691552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580800A Pending JP2024525492A (ja) | 2021-06-30 | 2022-06-29 | Ｃｄ７０陽性がんを標的とするポリペプチド |
Country Status (8)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG175426A1 (en) * | 2009-05-01 | 2011-12-29 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CA2937898A1 (en) * | 2014-01-24 | 2015-07-30 | Ngm Biopharmaceuticals, Inc. | Antibodies that bind to beta klotho and uses thereof |
| AU2019216420A1 (en) * | 2018-02-01 | 2020-08-20 | Pfizer Inc. | Chimeric antigen receptors targeting CD70 |
-
2022
- 2022-06-29 CA CA3224026A patent/CA3224026A1/en active Pending
- 2022-06-29 WO PCT/US2022/035441 patent/WO2023278520A1/en active Application Filing
- 2022-06-29 CN CN202280055290.2A patent/CN117897405A/zh active Pending
- 2022-06-29 US US18/567,967 patent/US20240269285A1/en active Pending
- 2022-06-29 MX MX2023015101A patent/MX2023015101A/es unknown
- 2022-06-29 EP EP22834113.7A patent/EP4363454A1/en active Pending
- 2022-06-29 AU AU2022303155A patent/AU2022303155A1/en active Pending
- 2022-06-29 JP JP2023580800A patent/JP2024525492A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7379561B2 (ja) | キメラ抗原及びｔ細胞受容体、並びに使用方法 | |
| US20240327533A1 (en) | Engineered immune cells targeting bcma and their uses thereof | |
| EP3564266A1 (en) | Novel chimeric antigen receptor and use thereof | |
| CA3094996A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| KR20230042703A (ko) | Bcma에 결합하는 키메라 항원 수용체 및 car-t 세포 | |
| CA3014067A1 (en) | Modified cells for immunotherapy | |
| TWI797610B (zh) | 人源化cd19抗體及其應用 | |
| CN112771167A (zh) | 表达有趋化因子的细胞及用途 | |
| JP2019510786A (ja) | 免疫療法におけるＴＧＦβの阻害 | |
| KR20230084470A (ko) | 면역 세포 기능의 향상 | |
| US20220056411A1 (en) | Methods for isolating cd8+ selected t cells | |
| US20240226154A9 (en) | Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same | |
| KR20230155521A (ko) | 면역 세포 기능의 향상 | |
| US20220325241A1 (en) | Immune effector cell for co-expressing chemokine receptor | |
| US20230321242A1 (en) | Chimeric antigen receptor (car)-expressing cells recognizing cea | |
| US20240009310A1 (en) | A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6 | |
| JPWO2023278520A5 (enrdf_load_stackoverflow) | ||
| WO2024230793A1 (en) | Chimeric antigen receptors and methods of use thereof | |
| KR20250089551A (ko) | 입양 세포 요법과 표적 면역사이토카인을 조합하여 이용한 암 치료 방법 | |
| WO2023246578A1 (zh) | 特异性结合gpc3的嵌合抗原受体及其应用 | |
| CN117881695A (zh) | 功能强化的新型嵌合抗原受体 | |
| CN118234755A (zh) | 特异性结合msln的嵌合抗原受体及其应用 |